There is an urgent need to develop effective therapies for COVID-19. Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients.

Complement as a target in COVID-19?

Ciceri F.
Penultimo
;
2020-01-01

Abstract

There is an urgent need to develop effective therapies for COVID-19. Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients.
2020
Betacoronavirus
Complement Inactivating Agents
Complement System Proteins
Coronavirus Infections
Drug Delivery Systems
Humans
Immunotherapy
Pandemics
Pneumonia, Viral
Respiratory Distress Syndrome, Adult
Complement Activation
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/105085
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 382
  • ???jsp.display-item.citation.isi??? 359
social impact